ValuEngine cut shares of Arcadia Biosciences (NASDAQ:RKDA) from a buy rating to a hold rating in a report released on Thursday morning, ValuEngine reports.

RKDA has been the topic of a number of other research reports. National Securities restated a buy rating and issued a $16.00 price target on shares of Arcadia Biosciences in a research report on Tuesday, May 26th. HC Wainwright restated a buy rating and issued a $14.00 price target on shares of Arcadia Biosciences in a research report on Tuesday, May 19th.

RKDA stock traded down $0.09 during trading hours on Thursday, hitting $3.85. 216,857 shares of the stock were exchanged, compared to its average volume of 314,147. The company has a current ratio of 4.09, a quick ratio of 3.06 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $34.10 million, a P/E ratio of -2.36 and a beta of -0.81. The company has a 50-day simple moving average of $3.94 and a two-hundred day simple moving average of $4.30. Arcadia Biosciences has a 12 month low of $1.82 and a 12 month high of $10.20.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Wednesday, May 13th. The basic materials company reported $0.29 earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.84. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.60 million. Arcadia Biosciences had a negative return on equity of 180.70% and a negative net margin of 1,035.38%. On average, equities research analysts predict that Arcadia Biosciences will post -1.93 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its position in shares of Arcadia Biosciences by 28.2% during the first quarter. Morgan Stanley now owns 13,878 shares of the basic materials company’s stock worth $40,000 after acquiring an additional 3,052 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Arcadia Biosciences by 263.2% during the first quarter. Wells Fargo & Company MN now owns 16,343 shares of the basic materials company’s stock worth $46,000 after acquiring an additional 11,843 shares during the last quarter. Oxford Asset Management LLP bought a new position in shares of Arcadia Biosciences during the fourth quarter worth about $191,000. Finally, Geode Capital Management LLC raised its position in shares of Arcadia Biosciences by 21.3% during the fourth quarter. Geode Capital Management LLC now owns 38,223 shares of the basic materials company’s stock worth $209,000 after acquiring an additional 6,708 shares during the last quarter. 5.07% of the stock is currently owned by institutional investors and hedge funds.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Further Reading: Fundamental Analysis and Individual Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.